#SAE continues to move up, 15p mid now, £64.4m mkt cap. Times article yesterday clearing helping.
The source also alludes to the EPC contractors potentially providing funding, and helping secure export credits from Chinese gov.
Clearly mgmt. is looking to avoid PLC dilution 1/5
I've been asked a few times about my rationale for the 2-year, £1bn mkt cap target.
There are ~2,500 coal-fired power plants in operation worldwide. Decommissioning costs average around $10m.
#SAE could pick up end-of-life plants from owners who don't wish to deal with... 2/5
decom. for next to nothing. $10m per plant would of course be a net gain to the owner of $20m.
Each converted plant could generate EBITDA of £40m for a further 2 decades.
Once Uskmouth has been completed, #SAE will have a converison template which they'll refine over time. 3/5
Coal burning and non-recyclable plastics are two monumental subjects that mankind is trying to address. #SAE's power plant conversion blueprint addresses both of them.
Conversion of just 1% of coal plants worldwide over the next decade would create a £1bn EBITDA portfolio. 4/5
With financial close due in Q4, I think the market will begin to consider #SAE's potential. The only remaining major technological hurdle - the large scale fuel testing - hopefully will be cleared shortly. Then it's full steam ahead, and hopefully more conversion projects. 5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6